Intensification of therapy using hematopoietic stem-cell support for high-risk neuroblastoma

Pediatric Transplantation

Volumn 3, Issue SUPPL. 1, 1999, Pages 72-77

  Matthay, Katherine K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

MYCN; Neuroblastoma; Purging bone marrow transplantation

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; ISOTRETINOIN; MELPHALAN; MONOCLONAL ANTIBODY; TENIPOSIDE; TUMOR VACCINE;

BONE MARROW; CANCER STAGING; CONFERENCE PAPER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; NEUROBLASTOMA; PROGNOSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; NEUROBLASTOMA; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 0032725162     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.1999.00070.x     Document Type: Conference Paper

References (37)

1. MATTHAY KK. Neuroblastoma: biology and therapy. Oncology 1997: 11: 1857-1866. [Discussion 1869-72, 1875.].
2. SEEGER RC, BRODEUR GM, SATHER H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985: 313: 1111-1116.
3. SUZUKI T, BOGENMANN E, SHIMADA H, STRAM D, SEEGER RC. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 1993: 85: 377-384. [See comments.]
4. BRODEUR GM, MARIS JM, YAMASHIRO DJ, HOGARTY MD, WHITE PS. Biology and genetics of human neuroblastomas. J Pediatr Hematol Oncol 1997: 19: 93-101.
5. SHIMADA H, STRAM DO, CHATTEN J, et al. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst 1995: 87: 1470-1476.
6. MATTHAY KK. Neuroblastoma: a clinical challenge and biologic puzzle. CA Cancer J Clin 1995: 45: 179-192.
7. BRODEUR GM, PRITCHARD J, BERTHOLD F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993: 11: 1466-1477. [See comments.]
8. SEEGER RC, VILLABLANCA JG, MATTHAY KK, et al. Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastoma. Prog Clin Biol Res 1991: 366: 527-533.
9. PHILIP T, ZUCKER JM, BERNARD JL, et al. Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: is cure possible in a small subgroup? J Clin Oncol 1991: 9: 1037-1044.
10. DINI G, LANINO E, GARAVENTA A, et al. Myeloablative therapy and unpurged autologous bone marrow transplantation for poor-prognosis neuroblastoma: report of 34 cases. J Clin Oncol 1991: 9: 962-969.
11. GRAHAM-POLE J, GEE A, EMERSON S, et al. Myeloablative chemoradiotherapy and autologous bone marrow infusions for treatment of neuroblastoma: factors influencing engraftment. Blood 1991: 78: 1607-1614.
12. MATTHAY KK, ATKINSON JB, STRAM DO, SELCH M, REYNOLDS CP, SHEGER RC. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study. J Clin Oncol 1993: 11: 2226-2233.
13. STRAM DO, MATTHAY KK, O'LEARY M, et al. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. J Clin Oncol 1996: 14: 2417-2426. [See comments.]
14. CHEUNG NV, HELLER G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 1991: 9: 1050-1058. [See comments.].
15. KUSHNER BH, LAQUAGLIA MP, BONILLA MA, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 1994: 12: 2607-2613.
16. CAMPBELL LA, SEEGER RC, HARRRIS RE, VILLABLANCA JG, MATTHAY KK. Escalating dose of continuous infusion combination chemotherapy for refractory neuroblastoma. J Clin Oncol 1993: 11: 623-629.
17. LADENSTEIN R, PHILIP T, LASSET C, et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 1998: 16: 953-965.
18. DINI G, LANINO E, GARAVENTA A, et al. Unpurged autologous bone marrow transplantation for neuroblastoma: the AIEOP-BMT group experience. Bone Marrow Transplant 1991: 7 (Suppl. 3): 109-111.
19. OHNUMA N, TAKAHASHI H, KANEKO M, et al. Treatment combined with bone marrow transplantation for advanced neuroblastoma: an analysis of patients who were pretreated intensively with the protocol of the Study Group of Japan. Med Pediatr Oncol 1995: 24: 181-187.
20. KUSHNER BH, O'REILLY RJ, MANDELL LR, GULATI SC, LAQUAGLIA M, CHEUNG NK. Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. J Clin Oncol 1991: 9: 274-279.
21. HARTMANN O, BENHAMOU E, BEAUJEAN F, et al. Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma. J Clin Oncol 1987: 5: 1205-1211.
22. MATTHAY KK, SEEGER RC, REYNOLDS CP, et al. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Children's Cancer Group. J Clin Oncol 1994: 12: 2382-2389.
23. VILLABLANCA JG, REYNOLDS CP, SWIFT PS, et al. Phase I trial of carboplatin, etoposide, melphalan and local irradiation (CEM-LI) with purged autologous marrow transplantation for children with high risk neuroblastoma. Proc Am Soc Clin Oncol 1998: 17: 533a.
24. MOSS TJ, REYNOLDS CP, SATHER HN, ROMANSKY SG, HAMMOND GD, SEEGER RC. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 1991: 324: 219-226.
25. RILL DR, SANTANA VM, ROBERTS WM, et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994: 84: 380-383.
26. KALRA R, ZOGER S, KOSOVICH MS, MATTHAY KK. Radiological case of the month. Miliary pulmonary neuroblastoma. Arch Pediatr Adolesc Med 1995: 149: 195-196.
27. MATTHAY KK, REYNOLDS CP, STRAM DO, SEEGER RC. Bone marrow immunocytology (BMI) as an early predictor of response in high risk neuroblastoma: a CCG study. Proc Am Soc Clin Oncol 1997: 16: 512a.
28. MATTANO LAJ, MOSS TJ, EMERSON SG. Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptase polymerase chain reaction. Cancer Res 1992: 52: 4701-4705.
29. MOSS TJ. Sensitive detection of metastatic tumor cells in bone marrow. Prog Clin Biol Res 1994: 389: 567-577.
30. MATTHAY KK, VILLABLANCA JG, SEEGER RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, purged autologous bone marrow transplantation and 13-cis-retinoic acid. N Engl J Med 1999: in press.
31. REYNOLDS CP, VILLABLANCA JG, STRAM DO, HARRIS R, SEEGER RC, MATTHAY KK. 13-cis-retinoic acid after intensive consolidation therapy for neuroblastoma improves event-free survival: a randomized Children's Cancer Group (CCG) study. Proc Am Soc Clin Oncol 1998: 17: 2a.
32. CHEUNG NK, MIRALDI FD. Iodine 131 labeled GD2 monoclonal antibody in the diagnosis and therapy of human neuroblastoma. Prog Clin Biol Res 1988: 271: 595-604.
33. MATTHAY KK, DESANTES K, HASEGAWA B, et al. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998: 16: 229-236.
34. FROST JD, HANK JA, REAMAN GH, et al. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer 1997: 80: 317-333.
35. OZKAYNAK MF, SEEGER RC, KRAILO M, SONDEL P, MATTHAY K, REAMAN G. Phase I study of chimeric human/murine anti-GD2 monoclonal antibody (ch14.18) with GM-CSF in children with neuroblastoma immediately post hematopoietic stem cell transplantation (HSCT): a Children's Cancer Group study. Proc Am Soc Clin Oncol 1998: 17: 532a.
36. BASNIEWSKI PG, REID JM, VILLABLANCA JG, REYNOLDS CP, AMES MM. A phase I pharmacokinetic study of fenretinide (HPR) in children with high-risk solid tumors. A Children's Cancer Group (CCG) Study. Proc Am Assoc Cancer Res 1999: 40: 92.
37. SHUSTER JJ, CANTOR AB, MCWILLIAMS N, et al. The prognostic significance of autologous bone marrow transplant in advanced neuroblastoma. J Clin Oncol 1991: 9: 1045-1049. [See comments.]